NCT03721263View on ClinicalTrials.gov

Study of ASLAN004 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

March 27, 2019

Study Completion Date

June 20, 2019

Conditions
Allergic Disorder
Interventions
BIOLOGICAL

ASLAN004

Single Dose

Trial Locations (1)

Unknown

CGH Clinical Trials & Research Unit, Singapore

Sponsors
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

ASLAN Pharmaceuticals

OTHER